News
Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living with chronic lung diseases such as bronchiectasis, cystic fibrosis and chronic ...
18d
Medindia on MSNGoodbye Antibiotics? Nose Robots Might Be the Future of Sinus Infection TreatmentResearchers estimate that, depending on regulatory approvals and safety trials, these nose robots might be ready for hospitals in three to five years, or up to a decade. They could also be adapted in ...
Citation: Qin X, Wang S, Yan Z, Zhao N and Yao J (2025) The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled spaces behind the nose, eyes and cheeks). Patients with chronic ...
Three recruited only patients with chronic rhinosinusitis without nasal polyps, one recruited patients with chronic rhinosinusitis with nasal polyps and one had a mixed population. Three followed up ...
PurposeThis review aims to explore the pathophysiological mechanisms and emerging therapies for type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), dri ...
Tiny magnetic bots that are activated by light can clear bacterial infections deep in the sinus cavities, then be expelled by blowing out the nose.
While the main underlying cause of acute rhinosinusitis (ARS) is probably bacterial in origin, the central pathophysiologic mechanisms of CRS remain to be fully elucidated. Several possible ...
Davis suffers from chronic sinusitis, a condition where inflammation of the sinus lining causes debilitating symptoms. He tried everything from antibiotics and a nebulizer to multiple surgeries and ...
The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) published the new Clinical Practice Guideline (CPG): Surgical Management of Chronic Rhinosinusitis today in ...
Patients with chronic rhinosinusitis with nasal polyps experienced greater improvements in symptoms with dupilumab compared with placebo, with differences emerging as early as 4 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results